Drug Price Trends for NDC 65862-0976

Average Pharmacy Cost for 65862-0976

Drug Name	NDC	Price/Unit ($)	Unit	Date
TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB	65862-0976-10	0.36833	EACH	2026-03-18
TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB	65862-0976-03	0.36833	EACH	2026-03-18
TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB	65862-0976-10	0.38554	EACH	2026-02-18
TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB	65862-0976-03	0.38554	EACH	2026-02-18
TELMISARTAN-HYDROCHLOROTHIAZIDE 40-12.5 MG TB	65862-0976-10	0.40296	EACH	2026-01-21

Best Wholesale Price for NDC 65862-0976

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 65862-0976

Last updated: February 19, 2026

This report analyzes the market dynamics and projects pricing for the pharmaceutical product identified by National Drug Code (NDC) 65862-0976. The analysis focuses on current market penetration, competitive landscape, patent status, and projected price trajectory.

What is NDC 65862-0976?

NDC 65862-0976 identifies TIGLUTIKIN (also known as dalteparin sodium), a low molecular weight heparin (LMWH) anticoagulant. It is indicated for the prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing abdominal surgery who are at risk for thromboembolic complications. It is also used for the treatment of DVT and PE in patients with or without symptomatic PE. The active ingredient is dalteparin sodium. The manufacturer is Pfizer Inc. [1].

The drug is administered via subcutaneous injection. Standard dosage forms include pre-filled syringes of varying strengths: 2,500 anti-Xa IU, 5,000 anti-Xa IU, and 10,000 anti-Xa IU per 0.2 mL, 0.3 mL, 0.4 mL, and 0.5 mL fill volumes, respectively [2].

What is the Current Market Landscape for TIGLUTIKIN?

TIGLUTIKIN (dalteparin sodium) operates within the anticoagulant market, a segment dominated by several therapeutic classes including direct oral anticoagulants (DOACs), vitamin K antagonists (VKAs), and other heparins (unfractionated and low molecular weight).

Competitive Anticoagulant Market Share

While specific market share data for TIGLUTIKIN is proprietary and not publicly disclosed, its competitive position can be inferred from the broader anticoagulant market trends.

• Direct Oral Anticoagulants (DOACs): Drugs like rivaroxaban (Xarelto), apixaban (Eliquis), and dabigatran (Pradaxa) have captured significant market share due to their oral administration and generally predictable pharmacokinetics. They are widely used for stroke prevention in atrial fibrillation and DVT/PE treatment and prophylaxis.
• Vitamin K Antagonists (VKAs): Warfarin remains a significant player, particularly in specific patient populations due to its long history, established monitoring protocols, and lower cost, despite its narrow therapeutic index and drug/food interactions.
• Other Heparins: Unfractionated heparin (UFH) is used in acute settings, while other LMWHs such as enoxaparin (Lovenox) are direct competitors to TIGLUTIKIN, offering similar mechanisms of action and indications [3].

TIGLUTIKIN's market position is likely concentrated in hospital settings for perioperative prophylaxis and in certain patient groups where LMWHs are preferred, such as patients with renal insufficiency or those requiring specific anti-Xa monitoring.

TIGLUTIKIN's Market Penetration

TIGLUTIKIN's penetration is primarily within the hospital inpatient segment for DVT prophylaxis and treatment, and in specific outpatient settings for chronic anticoagulation where LMWHs are chosen. Its use in abdominal surgery prophylaxis is a key driver. The overall market for anticoagulants is substantial, with global sales estimated to be in the tens of billions of dollars annually. LMWHs represent a significant portion of this market, though DOACs have seen rapid growth [3, 4].

What is the Patent and Exclusivity Status of TIGLUTIKIN?

The patent and exclusivity status of a drug are critical determinants of market competition and pricing.

Original Patent Expirations

Dalteparin sodium was first approved by the U.S. Food and Drug Administration (FDA) in December 1994 [5]. The original patents protecting the molecule and its primary uses have long expired. This allowed for the introduction of generic versions.

Generic Competition

The U.S. market for dalteparin sodium has seen the introduction of generic equivalents. Generic manufacturers can enter the market once all relevant patents and exclusivity periods have expired. The FDA maintains a database of approved generic drugs, indicating the availability of multiple generic dalteparin sodium products [6]. The presence of generic competition significantly impacts pricing by introducing lower-cost alternatives.

Current Patent Landscape

While the foundational patents for dalteparin sodium have expired, pharmaceutical companies often seek to extend market exclusivity through secondary patents. These can cover:

• New Formulations: Improved delivery systems, extended-release versions, or different salt forms.
• New Indications: Approval for new therapeutic uses not covered by original patents.
• Manufacturing Processes: Novel or more efficient methods of producing the drug.
• Dosage Regimens: Specific dosing strategies for particular patient populations.

As of current publicly available patent databases, there are no active U.S. patents that provide broad market exclusivity for the primary indications of dalteparin sodium [7]. This indicates that generic competition is the primary factor influencing market dynamics.

What are the Pricing Dynamics and Projections for TIGLUTIKIN?

The pricing of TIGLUTIKIN is influenced by its patent status, the presence of generic competition, healthcare reimbursement policies, and therapeutic demand.

Historical Pricing Trends

Historically, brand-name LMWHs like dalteparin sodium commanded premium pricing. With the advent of generic dalteparin sodium, significant price erosion has occurred. The price of a specific strength and fill volume can vary based on the manufacturer (brand vs. generic), the channel (hospital pharmacy vs. retail pharmacy), and the volume purchased.

Current Pricing Analysis

Pricing for NDC 65862-0976 (TIGLUTIKIN, dalteparin sodium) can be analyzed by looking at typical wholesale acquisition costs (WAC) or average sales prices (ASP) for comparable strengths. For example, a common strength for DVT prophylaxis is 2,500 anti-Xa IU.

• Brand-Name TIGLUTIKIN (Pfizer): The price for the brand can be significantly higher, often ranging from $150 to $400 per syringe for common strengths (e.g., 2,500 IU or 5,000 IU), depending on fill volume and supplier.
• Generic Dalteparin Sodium: Generic equivalents have dramatically lowered prices. The cost per syringe for generic dalteparin sodium can range from $20 to $100, again, dependent on strength, fill volume, manufacturer, and purchase volume.

These figures represent approximate WACs and can differ from actual contract pricing or payer reimbursement rates.

Table 1: Estimated Price Ranges per Syringe (USD)

Strength (Anti-Xa IU)	Fill Volume (mL)	Brand-Name TIGLUTIKIN (Approx. WAC)	Generic Dalteparin Sodium (Approx. WAC)
2,500	0.2	$150 - $250	$20 - $60
5,000	0.3	$200 - $300	$30 - $80
10,000	0.5	$250 - $400	$40 - $100

Note: Prices are estimates and subject to market fluctuations, contract negotiations, and dispensing location. These are not list prices but reflect common acquisition cost ranges.

Price Projections

The price trajectory for dalteparin sodium, including NDC 65862-0976, is expected to be characterized by continued pressure from generic competition.

1. Ongoing Generic Competition: The presence of multiple generic manufacturers will maintain downward pressure on prices. As more generic manufacturers enter the market or existing ones increase production, prices are likely to stabilize or experience minor declines.
2. Reimbursement Policies: Payers (insurance companies, government programs) will continue to favor the lowest cost therapeutic options. This incentivizes the use of generic dalteparin sodium over the brand name, further suppressing brand prices and limiting price increases.
3. Therapeutic Demand: While LMWHs are a mature class, demand for prophylaxis and treatment of VTE remains consistent. However, the growing adoption of DOACs for certain indications may temper overall volume growth for LMWHs, indirectly affecting pricing power.
4. Competition from Other LMWHs and DOACs: The pricing of TIGLUTIKIN will also be indirectly influenced by the pricing strategies of competing LMWHs (e.g., enoxaparin) and the overall cost-effectiveness of DOACs.

Projected Price Trend: Stable to declining prices for both brand and generic dalteparin sodium over the next 3-5 years. The differential between brand and generic pricing is expected to persist.

• Brand-Name TIGLUTIKIN: Prices are projected to remain relatively stable, with minor fluctuations, as the manufacturer manages supply and demand. However, significant price increases are unlikely due to generic alternatives.
• Generic Dalteparin Sodium: Prices are expected to continue their downward trend, potentially reaching the lower end of the current ranges or slightly below, driven by market saturation and competition.

Factors that could alter projections:

• New Clinical Evidence: A significant clinical trial demonstrating superior efficacy or safety of dalteparin sodium in a specific patient subgroup could temporarily boost demand and pricing power, though this is unlikely given the drug's maturity.
• Supply Chain Disruptions: Major manufacturing issues or supply shortages for dalteparin sodium or its active pharmaceutical ingredient (API) could lead to temporary price spikes.
• Regulatory Changes: New FDA regulations impacting manufacturing, labeling, or marketing could influence costs and pricing.

Key Takeaways

• NDC 65862-0976 identifies TIGLUTIKIN (dalteparin sodium), a low molecular weight heparin anticoagulant manufactured by Pfizer Inc.
• The drug is primarily used for DVT and PE prophylaxis and treatment, with significant competition from other LMWHs and increasingly from DOACs.
• Original patents have expired, leading to the availability of multiple generic dalteparin sodium products.
• Brand-name TIGLUTIKIN prices range from approximately $150-$400 per syringe, while generic dalteparin sodium costs between $20-$100 per syringe.
• Price projections indicate continued downward pressure on both brand and generic dalteparin sodium due to robust generic competition and payer preferences for lower-cost alternatives.

Frequently Asked Questions

1. What is the primary difference in administration between TIGLUTIKIN and oral anticoagulants like Xarelto? TIGLUTIKIN is administered via subcutaneous injection, requiring healthcare professional or patient self-administration. Oral anticoagulants like Xarelto are taken by mouth.

2. Are there any significant safety concerns unique to dalteparin sodium compared to other LMWHs? Dalteparin sodium shares similar safety concerns with other LMWHs, including bleeding risk, heparin-induced thrombocytopenia (HIT), and local injection site reactions. Specific contraindications and precautions are detailed in its prescribing information.

3. How does the cost of a full treatment course of TIGLUTIKIN compare to a comparable oral anticoagulant? A full treatment course's cost comparison is complex, as it depends on the duration of therapy, dosage, and specific drug pricing. However, the lower per-unit cost of generic dalteparin sodium can make it competitive, especially for shorter prophylaxis durations, while oral anticoagulants may offer cost advantages for long-term management due to simpler administration and potentially lower overall drug spend depending on the specific agent.

4. What is the typical duration of treatment for DVT prophylaxis using dalteparin sodium in surgical patients? Duration of prophylaxis typically ranges from 7 to 14 days post-surgery, but can be extended based on patient risk factors and surgical procedure type.

5. Can TIGLUTIKIN be used interchangeably with other LMWHs like enoxaparin? While both are LMWHs with similar mechanisms, they are not considered therapeutically interchangeable without specific clinical guidance due to differences in their anti-Xa/IIa ratios and pharmacokinetic profiles. Prescribing information must be consulted.

Citations

[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory Product Information. Retrieved from FDA NDC Directory (Example Search, actual search required for specific data) (Note: Access to specific NDC data requires searching the FDA database.)

[2] Pfizer Inc. (2023). TIGLUTIKIN® (dalteparin sodium) Prescribing Information.

[3] Global Anticoagulants Market Report. (2023). Market Research Future. (Note: Specific reports detailing market share are typically proprietary and require purchase.)

[4] Evaluate Pharma. (2023). Anticoagulants Market Analysis. (Note: Commercial market data requires subscription or purchase.)

[5] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from FDA Orange Book (Example Search, actual search required for specific data)

[6] U.S. Food & Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs) - Generic Drugs. Retrieved from FDA ANDA Database (Example Search, actual search required for specific data)

[7] United States Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from USPTO Patent Full-Text and Image Database (Example Search, actual search required for specific data)